https://www.selleckchem.com/pr....oducts/ag-120-Ivosid
After six months, 21 patients (60%) achieved disease remission. The median serum IgG4 concentration decreased from 1344 to 575 mg/L (p 0.01), and the median IgG4-RD RI decreased from 7.5 to 0 (p 0.01). B-cell depletion was observed in all patients. Eight patients (36%) relapsed within 18 months. Side effects related to RTX-B administration were observed in 14 patients (37%). These results are in line with our previous experience with RTX-O. The (Truxima ) rituximab biosimilar CT-P10 represents a safe and effective al
Like
Comment
Share
